What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Dose form - tablet Route of administration - oral Regimen / Treatment period - QD for 14 days”In the company’s words, NCT07403552 on ClinicalTrials.gov
- Main trialPhase 1
- “The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of NSHO-101 in Healthy Participants.”In the company’s words, NCT07403552 on ClinicalTrials.gov
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Mar 2026 | Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026